These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
140 related articles for article (PubMed ID: 15164882)
1. Estrogen receptors and anti-estrogen therapies. Buluwela L; Constantinidou D; Pike J; Ali S Cancer Treat Res; 2004; 119():271-92. PubMed ID: 15164882 [No Abstract] [Full Text] [Related]
2. Tamoxifen therapy--long-term results and complications. Moore MP; Kinne DW Adv Surg; 1996; 29():263-9. PubMed ID: 8720007 [No Abstract] [Full Text] [Related]
3. Mechanisms of tamoxifen resistance. Ring A; Dowsett M Endocr Relat Cancer; 2004 Dec; 11(4):643-58. PubMed ID: 15613444 [TBL] [Abstract][Full Text] [Related]
4. [New developments in hormonal therapy for breast cancer]. Tominaga T Gan To Kagaku Ryoho; 1996 May; 23(6):678-83. PubMed ID: 8645017 [TBL] [Abstract][Full Text] [Related]
5. Tamoxifen in early breast cancer. Arriagada R Lancet; 1998 Aug; 352(9125):403-4. PubMed ID: 9717953 [No Abstract] [Full Text] [Related]
6. Tamoxifen in early breast cancer. Bryce CJ Lancet; 1998 Aug; 352(9125):403. PubMed ID: 9717952 [No Abstract] [Full Text] [Related]
8. Tamoxifen in early breast cancer. Benson JR Lancet; 1998 Aug; 352(9125):404-5. PubMed ID: 9717955 [No Abstract] [Full Text] [Related]
9. Mechanisms of tamoxifen resistance in the treatment of advanced breast cancer. Lykkesfeldt AE Acta Oncol; 1996; 35 Suppl 5():9-14. PubMed ID: 9142958 [TBL] [Abstract][Full Text] [Related]
10. [Modern approaches to estrogen-independent growth of breast tumor]. Krasil'nikov MA Vopr Onkol; 2004; 50(4):399-405. PubMed ID: 15605761 [No Abstract] [Full Text] [Related]
11. Reliability of estrogen receptors in predicting response to antiestrogens. Valavaara R Oncology (Williston Park); 1997 May; 11(5 Suppl 4):14-8. PubMed ID: 9165501 [TBL] [Abstract][Full Text] [Related]
12. Tamoxifen, balancing risks and benefits. Bergman L; Benraadt J; van Leeuwen FE Neth J Med; 1996 Dec; 49(6):228-34. PubMed ID: 8990861 [No Abstract] [Full Text] [Related]
13. [Action of SERM and SAS (tibolone) on breast tissue]. Gompel A; Jacob D; de Chambine S; Mimoun M; Decroix Y; Rostene W; Poitout P Contracept Fertil Sex; 1999 May; 27(5):368-75. PubMed ID: 10401183 [TBL] [Abstract][Full Text] [Related]
14. Endocrine therapy in breast cancer. Johnson AE Lancet; 1996 Mar; 347(9003):761. PubMed ID: 8602017 [No Abstract] [Full Text] [Related]
16. Tamoxifen and contralateral breast cancer: the other side. Swain SM J Natl Cancer Inst; 2001 Jul; 93(13):963-5. PubMed ID: 11438553 [No Abstract] [Full Text] [Related]
17. Endocrine therapy of endometrial cancer. Lentz SS Cancer Treat Res; 1998; 94():89-106. PubMed ID: 9587684 [No Abstract] [Full Text] [Related]
18. Tamoxifen and menopausal status: risks and benefits. Sasco AJ Lancet; 1996 Mar; 347(9003):761. PubMed ID: 8602018 [No Abstract] [Full Text] [Related]
19. Tamoxifen versus raloxifene in the prevention of breast cancer. Wickerham DL Eur J Cancer; 2002 Nov; 38 Suppl 6():S20-1. PubMed ID: 12409060 [No Abstract] [Full Text] [Related]
20. [Does anti-estrogen therapy after estrogen receptor analysis have value in palliative therapy of hepatocellular carcinoma?]. Kreysel C; Porschen R Z Gastroenterol; 1998 Jul; 36(7):605-7. PubMed ID: 9738309 [No Abstract] [Full Text] [Related] [Next] [New Search]